AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25904220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23973139 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge pain management behaviors and pain intensity assessment
Number of subjects: 171
Study 23973139 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on analgesics and non-pharmacological methods for pain relief
Number of subjects: 171
Study 23973139 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of analgesic use
Number of subjects: 171
Study 23973139 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and exercise times
Number of subjects: 171
Study 20734206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy performed by trainee surgeons in Group B (fibrotic pancreas)
Number of subjects: 72
Study 20734206 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy performed by experienced surgeons in Group A (normal pancreas)
Number of subjects: 72
Study 18485121 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU lutropin alfa with 150 IU follitropin alfa
Number of subjects: 39
Study 18485121 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 150 IU follitropin alfa
Number of subjects: 39
Study 15728810 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg of rFVIIa per kilogram
Number of subjects: 399
Study 15728810 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg of rFVIIa per kilogram
Number of subjects: 399
Study 15728810 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 microg of rFVIIa per kilogram
Number of subjects: 399
Study 15728810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 15728810 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (combined groups)
Number of subjects: 399
Study 15728810 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 399
Study 12610799 — intervention group
Group type: EXPERIMENTAL
Intervention: AG4263 (n = 24)
Number of subjects: 31
Study 12610799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 31
Study 10475314 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Number of subjects: 10
Study 10475314 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 0.5%
Number of subjects: 10
Study 8671164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cap with intracervical reservoir
Number of subjects: 198
Study 8671164 — intervention group
Group type: COMPARATOR
Intervention: Standard intracervical injection
Number of subjects: 198
Study 1754839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX, 1%)
Number of subjects: 45
Study 1754839 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2-amine fluoride (AmF) combination (F-content 1.20%)
Number of subjects: 45
Study 1754839 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (control group)
Number of subjects: 45
Study 7048657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (median 1.45 x 10(10) granulocytes, range 0.28‐3.45 x 10(10))
Number of subjects: 24
Study 7048657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions
Number of subjects: 24
Study 31714191 — intervention group
Group type: EXPERIMENTAL
Intervention: FE2mg (2 mg/kg)
Number of subjects: 12
Study 31714191 — intervention group
Group type: EXPERIMENTAL
Intervention: FE4mg (4 mg/kg)
Number of subjects: 12
Study 31714191 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 31171029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin/tazobactam (TZP) guided by daily therapeutic drug monitoring (TDM)
Number of subjects: 0
Study 31171029 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of total daily dose of TZP without TDM guidance (13.5 g TZP in normal renal function)
Number of subjects: 0
Study 31171029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of TZP guided by daily TDM
Number of subjects: 0
Study 31171029 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of TZP without TDM guidance
Number of subjects: 0
Study 28536015 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 48
Study 28536015 — intervention group
Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 48
Study 25886918 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized dosing
Number of subjects: 78
Study 25886918 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing
Number of subjects: 78
Study 23597054 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment including physical, cognitive, psychological and social functioning, lifestyle behaviour, physical environment, wellbeing and care utilisation
Number of subjects: 2942
Study 23597054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination including anthropometry, muscle strength, physical performance and OA exam
Number of subjects: 2942
Study 23597054 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment performed 12-18 months after baseline
Number of subjects: 2942
Study 21412996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine (80 ml)
Number of subjects: 80
Study 21412996 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 19663892 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg p.o. q12 h
Number of subjects: 25
Study 19663892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17873811 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston brace treatment
Number of subjects: 106
Study 17873811 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 106
Study 14526317 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of ampicillin
Number of subjects: 48
Study 14526317 — intervention group
Group type: COMPARATOR
Intervention: 7 days of ampicillin
Number of subjects: 48
Study 10601063 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 81
Study 10601063 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 81
Study 9190842 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of (S)-gallopamil
Number of subjects: 6
Study 9190842 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of pseudoracemic (RS)-gallopamil
Number of subjects: 6
Study 9190842 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of (R)-gallopamil
Number of subjects: 6
Study 9190842 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-gallopamil and (RS)-gallopamil
Number of subjects: 6
Study 9190842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9190842 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of (R)-gallopamil
Number of subjects: 6
Study 1398465 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-releasing hormone (GHRH)
Number of subjects: 7
Study 1398465 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 7
Study 1398465 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 7
Study 3893513 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-43179 gel
Number of subjects: 30
Study 3893513 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide (Synalar gel)
Number of subjects: 30
Study 31486722 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained hepatologist led palliative care (Model 2)
Number of subjects: 1260
Study 31486722 — intervention group
Group type: COMPARATOR
Intervention: Consultative palliative care (Model 1)
Number of subjects: 1260
Study 27139158 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 250 mg/d
Number of subjects: 697
Study 27139158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 697
Study 27139158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 697
Study 25982801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Genetic Score (PGS-33)
Number of subjects: 2244
Study 25982801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Specific Antigen (PSA)
Number of subjects: 2244
Study 25982801 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of prostate cancer
Number of subjects: 2244
Study 25982801 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS-33 quartiles
Number of subjects: 2244
Study 25982801 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA performance
Number of subjects: 2244
Study 23453081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral correction of the supraorbital rim
Number of subjects: 48
Study 23453081 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral correction of the supraorbital rim
Number of subjects: 48
Study 23453081 — intervention group
Group type: COMPARATOR
Intervention: Timing of surgery (before or after the age of 1 year)
Number of subjects: 48
Study 21838614 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical removal of pathologic mucosa with a power microdebrider (group A)
Number of subjects: 98
Study 21838614 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removal of pathologic mucosa (group B)
Number of subjects: 98
Study 21838614 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlargement of the maxillary ostium (group C)
Number of subjects: 98
Study 21838614 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 98
Study 20923540 — intervention group
Group type: EXPERIMENTAL
Intervention: LighterLife Programme (LL)
Number of subjects: 120
Study 20923540 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate/high-protein diet (LCHP)
Number of subjects: 120
Study 17701366 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting Coroflex Please stent
Number of subjects: 96
Study 15353828 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor (eptifibatide)
Number of subjects: 2064
Study 15353828 — intervention group
Group type: COMPARATOR
Intervention: Control (no glycoprotein IIb/IIIa inhibitor)
Number of subjects: 2064
Study 11444458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILM)
Number of subjects: 65
Study 10865393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofscale
Number of subjects: 32
Study 10865393 — intervention group
Group type: COMPARATOR
Intervention: Root planing alone
Number of subjects: 32
Study 10865393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofscale application after root planing
Number of subjects: 32
Study 8521099 — intervention group
Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 75
Study 8521099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 75
Study 8521099 — intervention group
Group type: COMPARATOR
Intervention: Natural course (no treatment)
Number of subjects: 75
Study 2232464 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin (10 mg/kg intravenously for 5 days, then 1 mg/kg intramuscularly for 15 days)
Number of subjects: 0
Study 2232464 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with myocardial infarction)
Number of subjects: 0
Study 343725 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive index measured using a gamma camera
Number of subjects: 16
Study 343725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30563846 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEAR (resilience-based intervention)
Number of subjects: 707
Study 30563846 — intervention group
Group type: COMPARATOR
Intervention: Usual training (control)
Number of subjects: 707
Study 28177565 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 201
Study 28177565 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry monitoring (Control)
Number of subjects: 201
Study 26119403 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-Balance Ultrafiltration (Z-BUF)
Number of subjects: 199
Study 26119403 — intervention group
Group type: COMPARATOR
Intervention: No Zero-Balance Ultrafiltration (no-Z-BUF)
Number of subjects: 199
Study 23816061 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10mg)
Number of subjects: 14
Study 23816061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21735945 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush
Number of subjects: 93
Study 21735945 — intervention group
Group type: COMPARATOR
Intervention: 3-month-old toothbrush
Number of subjects: 93
Study 19467806 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of dinoprostone gel 0.5mg (Prepidil) every 6 hours (group I)
Number of subjects: 148
Study 19467806 — intervention group
Group type: COMPARATOR
Intervention: Repeated doses of dinoprostone gel 0.5mg (Prepidil) every 12 hours (group II)
Number of subjects: 148
Study 16443860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (12 mg intravenously before reperfusion)
Number of subjects: 158
Study 16443860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously before reperfusion)
Number of subjects: 158
Study 12801074 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 0
Study 12801074 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 0
Study 12801074 — intervention group
Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 0
Study 10655907 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral bupivacaine
Number of subjects: 100
Study 10655907 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural bupivacaine
Number of subjects: 100
Study 8701417 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg
Number of subjects: 15
Study 8701417 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 500 mg
Number of subjects: 15
Study 8701417 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg b.i.d. for 7 days
Number of subjects: 15
Study 8701417 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg/d for 7 days
Number of subjects: 15
Study 2072190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triazolam
Number of subjects: 12
Study 2072190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6863645 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tetracycline (TCN)
Number of subjects: 0
Study 6863645 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tetracycline (TCN) preparation
Number of subjects: 0
Study 2858743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (250 mg)
Number of subjects: 80
Study 2858743 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (450 mg)
Number of subjects: 80
Study 2858743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (750 mg)
Number of subjects: 80
Study 2858743 — intervention group
Group type: COMPARATOR
Intervention: MSP (750 mg mefloquine plus 3 tablets of 'Fansidar')
Number of subjects: 80
Study 2858743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine and MSP (both groups)
Number of subjects: 80
Study 31141300 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 248
Study 31141300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 248
Study 31141300 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 248
Study 29505075 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrated video (vodcast)
Number of subjects: 42
Study 29505075 — intervention group
Group type: COMPARATOR
Intervention: Guided readings
Number of subjects: 42
Study 26684248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion
Number of subjects: 6
Study 26684248 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 6
Study 24885076 — intervention group
Group type: EXPERIMENTAL
Intervention: MusicGlove
Number of subjects: 12
Study 24885076 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand therapy
Number of subjects: 12
Study 24885076 — intervention group
Group type: COMPARATOR
Intervention: Isometric hand movement training
Number of subjects: 12
Study 21909033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pinning
Number of subjects: 1615
Study 21909033 — intervention group
Group type: COMPARATOR
Intervention: Cross pinning
Number of subjects: 1615
Study 20968112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg once a day)
Number of subjects: 120
Study 20968112 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times a day)
Number of subjects: 120
Study 20968112 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet control (diet recommendation)
Number of subjects: 120
Study 20968112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 18550975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined elastic and free weight resistance (CR)
Number of subjects: 44
Study 16494259 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n = 3687)
Number of subjects: 6405
Study 16494259 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (n = 2718)
Number of subjects: 6405
Study 12848632 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg once daily)
Number of subjects: 150
Study 12848632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12848632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of dyspepsia
Number of subjects: 150
Study 10641896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortune photoscreener
Number of subjects: 105
Study 10641896 — intervention group
Group type: EXPERIMENTAL
Intervention: MTI photoscreener
Number of subjects: 105
Study 8896773 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 11
Study 8896773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1829514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephalosporins
Number of subjects: 19
Study 1829514 — intervention group
Group type: COMPARATOR
Intervention: Oral penicillin
Number of subjects: 19
Study 1829514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cephalosporins and penicillins
Number of subjects: 19
Study 6357976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolgit Creme (5% ibuprofen) applied 3 or more times daily (4-10 cm strip)
Number of subjects: 464
Study 6357976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 31964449 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPH ER TAB 20 mg swallowed (fasted)
Number of subjects: 32
Study 31964449 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPH ER TAB 20 mg chewed (fed/fasted)
Number of subjects: 32
Study 31964449 — intervention group
Group type: COMPARATOR
Intervention: AMPH EROS 2.5 mg/mL (fasted)
Number of subjects: 32
Study 30912838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of 150 million allogeneic mesenchymal precursor cells (MPCs)
Number of subjects: 159
Study 30912838 — intervention group
Group type: COMPARATOR
Intervention: Cryoprotective medium (sham treatment)
Number of subjects: 159
Study 29705935 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week behavioral skills plus positive parenting and peer monitoring intervention
Number of subjects: 89
Study 29705935 — intervention group
Group type: COMPARATOR
Intervention: General health comparison program
Number of subjects: 89
Study 27107519 — intervention group
Group type: EXPERIMENTAL
Intervention: Orem's self-care nursing model (four 30-45 minutes training sessions)
Number of subjects: 88
Study 27107519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 24255129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg/day 20‐h infusion and 4‐h post‐infusion period)
Number of subjects: 71
Study 24255129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 71
Study 24255129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 22850511 — intervention group
Group type: EXPERIMENTAL
Intervention: VP20621 (10^4, 10^6, or 10^8 spores)
Number of subjects: 0
Study 22850511 — intervention group
Group type: EXPERIMENTAL
Intervention: VP20621 (10^8 spores twice a day)
Number of subjects: 0
Study 22850511 — intervention group
Group type: EXPERIMENTAL
Intervention: VP20621 (10^4, 10^6, or 10^8 spores daily) after vancomycin administration
Number of subjects: 0
Study 22850511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22850511 — intervention group
Group type: EXPERIMENTAL
Intervention: VP20621
Number of subjects: 0
Study 20492512 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg/week (PEG)
Number of subjects: 105
Study 20492512 — intervention group
Group type: COMPARATOR
Intervention: alpha‐tocopherol 1000 mg/day (TOCO)
Number of subjects: 105
Study 18606249 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assessment (daily diaries)
Number of subjects: 78
Study 18606249 — intervention group
Group type: COMPARATOR
Intervention: Standard weekly clinic assessment
Number of subjects: 78
Study 16020959 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg orally 3 times daily
Number of subjects: 56
Study 16020959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12449159 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 546
Study 12449159 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 546
Study 11120419 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 4.35 +/- 1.7 mg/day)
Number of subjects: 76
Study 11120419 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 10.56 +/- 4.9 mg/day)
Number of subjects: 76
Study 11120419 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean dose 10.01 +/- 6.1 mg/day)
Number of subjects: 76
Study 8898512 — intervention group
Group type: EXPERIMENTAL
Intervention: European version (ET)
Number of subjects: 500
Study 8898512 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian version (CT)
Number of subjects: 500